Pharmaceutical Therapies for Pediatric Respiratory Disease: Setbacks and Progress in 2024

Weixel N . A dispute over a common asthma drug leaves patients caught in the middle. 2024. Available from: https://thehill.com/policy/healthcare/4472283-a-dispute-over-a-common-asthma-drug-leaves-patients-caught-in-the-middle/ [Last accessed: August 23, 2024].

Amrathlal D . The Impact of AMP Cap Removal on Medicaid Drug Prices. 2024. Available from: https://www.iqvia.com/locations/united-states/blogs/2023/04/the-impact-of-amp-cap-removal-on-medicaid-drug-prices [Last accessed: August 23, 2024].

Bickel S , Morton R , O’Hagan A , et al. Impact of payor-initiated switching of inhaled corticosteroids on lung function. J Pediatr, 2021; 234:128–133.e121.

Payares-Salamanca L , Contreras-Arrieta S , Florez-García V , et al. Metered-dose inhalers versus nebulization for the delivery of albuterol for acute exacerbations of wheezing or asthma in children: A systematic review with meta-analysis. Pediatr Pulmonol, 2020; 55(12):3268–3278.

De Boeck K , Alifier M , Warnier G . Is the correct use of a dry powder inhaler (Turbohaler) age dependent? J Allergy Clin Immunol, 1999; 103(5 Pt 1):763–767.

Mometasone Furoate Oral Inhalers. 2024. Available from: https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=1026&loginreturnUrl=SSOCheckOnly#:∼:text=Estimated%20Resupply%20Dates,date%20of%20early%2DAugust%202024

Drug Companies Step Forward with Voluntary Price Caps on Inhalers. 2024. Available from: https://allergyasthmanetwork.org/news/drug-company-asthma-inhaler-price-cap/ [Last accessed: August 23, 2024].

Inhalers Are 78% Cheaper Via International Pharmacy Mailorder. 2022. Available from: https://www.pharmacychecker.com/news/inhalers-cheaper-via-international-mail-order/ [Last accessed: August 23, 2024].

Fasenra Approved for Treatment of Children Aged 6 to 11 with Severe Asthma. 2024. Available from: https://www.drugs.com/newdrugs/fasenra-approved-children-aged-6-11-severe-asthma-6245.html [Last accessed: August 23, 2024].

Wedner HJ , Fujisawa T , Guilbert TW , et al. all TATE investigators. Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study). Pediatr Allergy Immunol, 2024; 35(3):e14092.

Dupixent (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE). 2024. Available from: https://www.drugs.com/newdrugs/dupixent-dupilumab-fda-approved-first-only-indicated-children-aged-1-year-older-eosinophilic-6187.html [Last accessed: August 23, 2024].

Chehade M , Dellon E , Spergel J , et al. Dupilumab improves histologic and endoscopic outcomes in children aged 1 To <12 years with Eosinophilic Esophagitis (EoE): 52-week results from the Phase 3 EoE KIDS Trial. J Allergy Clin Immunol Pract, 2024; 153(2):AB266.

FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure. 2024. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-help-reduce-allergic-reactions-multiple-foods-after-accidental [Last accessed: August 23, 2024].

Wood RA , Togias A , Sicherer SH , et al. Omalizumab for the treatment of multiple food allergies. N Engl J Med, 2024; 390(10):889–899.

Pavord ID , Jackson D , Wechsler M , et al. SWIFT-1 and SWIFT-2 study design: Replicate Phase 3A randomized, double-blind, placebo-controlled, multicenter studies of the efficacy and safety of depemokimab in patients with asthma with an eosinophilic phenotype. C34.In: Biologic Therapy In The Fight Against Asthma And Allergic Inflammation. American Thoracic Society; 2024; A5384–A5384.

GSK Q2 2024 results Conference Call and Webcast for Investors and Analysts. 2024. Available from: https://www.gsk.com/media/11424/q2-2024-results-transcript.pdf [Last accessed: August 23, 2024].

Beaney A . GSK Boasts Win for Depemokimab in Asthma Trials. 2024. Available from: https://www.clinicaltrialsarena.com/news/gsk-pivotal-trials-depemokimab-positive/ [Last accessed: August 23, 2024].

Gupta S , Couillard S , Digby G , et al. Climate change and inhaler selection in patients with respiratory disease. Chest, 2024; 165(3):503–506.

Keeley D , Scullion JE , Usmani OS . Minimising the environmental impact of inhaled therapies: Problems with policy on low carbon inhalers. Eur Respir J, 2020; 55(2):2000048.

Wilkinson A , Woodcock A . The environmental impact of inhalers for asthma: A green challenge and a golden opportunity. Br J Clin Pharmacol, 2022; 88(7):3016–3022.

Market Characterizations. 2021. Available from: https://www.epa.gov/climate-hfcs-reduction/market-characterizations [Last accessed: August 23, 2024].

GSK Announces Major Step Towards Sustainability Ambitions with Advancement of Low Carbon Ventolin Programme to Phase III Trials. 2023. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-announces-major-step-towards-sustainability-ambitions-with-advancement-of-low-carbon-ventolin-programme-to-phase-iii-trials/#:∼:text=GSK%20plc%20(LSE%2FNYSE%3A,next%20generation%20propellant%2C%20in%202024 [Last accessed: August 23, 2024].

AstraZeneca Progresses Ambition Zero Carbon programme with Honeywell Partnership to Develop Next-Generation Respiratory Inhalers. 2022. Available from: https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-progresses-ambition-zero-carbon-programme-with-honeywell-partnership-to-develop-next-generation-respiratory-inhalers.html#! [Last accessed: August 23, 2024].

A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma. 2024. Available from: https://www.clinicaltrials.gov/study/NCT06502366 [Last accessed: August 23, 2024].

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma. 2024. Available from: https://www.clinicaltrials.gov/study/NCT06261957 [Last accessed: August 23, 2024].

Despotes KA , Donaldson SH . Current state of CFTR modulators for treatment of Cystic Fibrosis. Curr Opin Pharmacol, 2022; 65:102239.

Middleton PG , Mall MA , Dřevínek P , et al. VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del Allele. N Engl J Med, 2019; 381(19):1809–1819.

Uluer AZ , MacGregor G , Azevedo P , et al. VX18-561-101 Study Groups. Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: Randomised, double-blind, controlled, phase 2 trials. Lancet Respir Med, 2023; 11(6):550–562.

Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis. 2024. Available from: https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-pivotal-trials [Last accessed: August 23, 2024].

Vertex Pharmaceuticals Incorporated (VRTX) 41st Annual J.P. Morgan Healthcare Conference—(Transcript). Available from: https://seekingalpha.com/article/4568767-vertex-pharmaceuticals-incorporated-vrtx-41st-annual-j-p-morgan-healthcare-conference [Last accessed: January 31, 2023].

Ozeri-Galai E , Friedman L , Barchad-Avitzur O , et al. Delivery characterization of SPL84 inhaled antisense oligonucleotide Drug for 3849 + 10 kb C- > T cystic fibrosis patients. Nucleic Acid Ther, 2023; 33(5):306–318.

Lobo A . SPL84 therapy on FDA fast track for CF due to splicing mutation. 2024. Available from: https://cysticfibrosisnewstoday.com/news/spl84-fda-fast-track-cf-caused-splicing-mutation/ [Last accessed: August 23, 2024].

VX-522 mRNA. 2024. Available from: https://apps.cff.org/Trials/Pipeline/details/10204/VX-522-mRNA [Last accessed: August 23, 2024].

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF). 2024. Available from: https://clinicaltrials.gov/study/NCT05668741

Sun Y , Chatterjee S , Lian X , et al. In vivo editing of lung stem cells for durable gene correction in mice. Science, 2024; 384(6701):1196–1202.